Amyris, Inc.

Track this case

Case Number:

1:23-bk-11131

Court:

Delaware

Nature of Suit:

Firms

Companies

Government Agencies

Sectors & Industries:

  1. April 10, 2025

    Amyris Ch. 11 Trust Sues Ex-CEO Over $200M Skin Care Deal

    A creditor trust created under Amyris' Chapter 11 plan has sued the biotechnology company's former CEO in Delaware bankruptcy court, accusing him of abandoning his fiduciary duties by entering into a product licensing deal that locked in low prices for its cosmetics ingredients and contributed to the firm's insolvency.

  2. March 18, 2024

    ​​​​​​​Amyris Gets OK To Settle Pot Co.'s $15M Trade Secret Suit

    A Delaware bankruptcy judge has approved biotechnology company Amyris' $15.1 million settlement with cannabinoid manufacturer Lavvan, resolving yearslong litigation and arbitration proceedings alleging the debtor misused its then-business partner's trade secrets.

  3. February 02, 2024

    Judge Tosses Involuntary Releases In Amyris Ch. 11 Plan

    A Delaware bankruptcy judge on Friday struck down biotechnology company Amyris Inc.'s plan to shield executives and others from liability using nonconsensual releases as part of its Chapter 11 plan, finding that Amyris can reorganize without relying on the controversial mechanism.

  4. January 24, 2024

    Amyris Says Claim Releases Needed For Post-Ch. 11 Success

    Biotechnology company Amyris Inc. told a Delaware bankruptcy judge on Wednesday it needs to eliminate potential shareholder claims in order to emerge from its Chapter 11 case as a successful company.

  5. January 18, 2024

    SEC, US Trustee Object To Releases In Amyris' Ch. 11 Plan

    The U.S. Securities and Exchange Commission and the U.S. Trustee's Office have expressed new concerns about nonconsensual third-party releases in biotechnology company Amyris' Chapter 11 plan, arguing that such releases are only allowed in extraordinary circumstances that were not met by the debtor.

  6. January 09, 2024

    Amyris Fights Claims In Cannabis IP Row By Defining 'Under'

    Biotechnology company Amyris Inc. said Tuesday the word "under" in a contract between it and cannabinoid manufacturer Lavvan supports its effort to quash two claims Lavvan has filed against the debtor, telling a Delaware bankruptcy judge the plain meaning of the preposition bars the claims from going forward.

  7. December 20, 2023

    Biochemical Co. Amyris OK'd To Sell Celebrity Brands

    Bankrupt biochemical company Amyris Inc. can move forward with plans to sell its remaining consumer brands, a Delaware bankruptcy judge ruled Wednesday, after an auction last week raked in winning bids totaling $6 million.

  8. December 15, 2023

    Amyris Says DIP Lender Will Bid For Remaining Assets

    Synthesized biologicals producer Amyris told a Delaware bankruptcy court its debtor-in-possession and prepetition lenders will step in with a stalking horse credit bid for its core assets, unless the Northern California-based company receives a bid greater than $255 million at a Chapter 11 auction in January.

  9. December 12, 2023

    Amyris Gets OK To Solicit Ch. 11 Plan Votes

    A Delaware bankruptcy judge Tuesday allowed biochemical company Amyris Inc. to send its Chapter 11 plan out for a creditor vote, overriding objections tied to the plan's proposed third-party claim releases.

  10. December 11, 2023

    Amyris Creditors Slam 'Tainted' Ch. 11 Plan

    Noteholders and shareholders of bankrupt biochemical company Amyris Inc. have lodged an objection to its Chapter 11 plan and disclosure statement, contending the plan keeps creditors in the dark about the impact of its third-party releases and exemplifies a larger lack of transparency.